LENZ Therapeutics is a commercial-stage biopharmaceutical company based in San Diego, California, dedicated to developing and commercializing transformative ophthalmic therapies, led by VIZZ (aceclidine ophthalmic solution 1.44%), the first and only aceclidine-based eye drop for the treatment of presbyopia. In October 2026, LENZ initiated a corporate reorganization reducing workforce headcount by 75% (~120 roles) down to ~40 employees to focus capital on direct-to-consumer digital marketing and telehealth distribution while lowering projected 2027 OPEX by over 50%.
Formal CEO succession transition of Dan Chevallard as Interim President & CEO
Completion of 75% organizational restructuring and consumer marketing realignment
Commercial-stage ophthalmic developer LENZ Therapeutics disclosed in an SEC Form 8-K (Item 2.05) a strategic reorganization reducing headcount by approximately 75% down to roughly 40 full-time employees (~120 roles eliminated). The restructuring shifts commercial execution for its FDA-approved presbyopia eye drop VIZZ (aceclidine 1.44%) toward direct-to-consumer digital marketing and telehealth channels while cutting projected 2027 operating expenses by over 50% ($70M–$75M target), supported by $197.3M in cash and marketable securities as CEO Eef Schimmelpennink transitions to an advisory role.
LENZ Therapeutics disclosed an SEC Form 8-K restructuring cutting 75% of its workforce (~120 roles) down to 40 full-time employees, shifting capital toward direct-to-consumer digital marketing and telehealth for VIZZ while trimming projected 2027 OPEX by over 50%.
Chief Financial Officer and Interim President & CEO
Outgoing President & CEO (Strategic Advisor)
Chief Medical Officer
No active job listings. Check back later.